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Abstract
Background: A small number of individuals with B-cell-related primary immunodeficiency diseases (PIDs) may exhibit
long-term (prolonged or chronic) excretion of immunodeficiency-associated vaccine-derived polioviruses (iVDPVs)
following infection with oral poliovirus vaccine (OPV). These individuals pose a risk of live poliovirus reintroduction into
the population after global wild poliovirus eradication and subsequent OPV cessation. Treatment with polio antiviral
drugs may potentially stop excretion in some of these individuals and thus may reduce the future population risk.
Methods: We developed a discrete event simulation model to characterize the global prevalence of long-term iVDPV
excretors based on the best available evidence. We explored the impact of different assumptions about the
effectiveness of polio antiviral drugs and the fraction of long-term excretors identified and treated.
Results: Due to the rarity of long-term iVDPV excretion and limited data on the survival of PID patients in
developing countries, uncertainty remains about the current and future prevalence of long-term iVDPV
excretors. While the model suggests only approximately 30 current excretors globally and a rapid decrease
after OPV cessation, most of these excrete asymptomatically and remain undetected. The possibility that one
or more PID patients may continue to excrete iVDPVs for several years after OPV cessation represents a risk
for reintroduction of live polioviruses after OPV cessation, particularly for middle-income countries. With the
effectiveness of a single polio antiviral drug possibly as low as 40 % and no system in place to identify and
treat asymptomatic excretors, the impact of passive use of a single polio antiviral drug to treat identified
excretors appears limited. Higher drug effectiveness and active efforts to identify long-term excretors will
dramatically increase the benefits of polio antiviral drugs.
Conclusions: Efforts to develop a second polio antiviral compound to increase polio antiviral effectiveness and/or to
maximize the identification and treatment of affected individuals represent important risk management opportunities
for the polio endgame. Better data on the survival of PID patients in developing countries and more longitudinal data
on their exposure to and recovery from OPV infections would improve our understanding of the risks associated with
iVDPV excretors and the benefits of further investments in polio antiviral drugs.
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Introduction
The Global Polio Eradication Initiative (GPEI) plans to
stop the use of the oral poliovirus vaccine (OPV) after
assurance of global interruption of wild poliovirus
(WPV) transmission to eliminate the risks of poliomyel-
itis disease associated with continued OPV use [1, 2].
Given the apparent global interruption of indigenous
serotype 2 WPV (WPV2) by 2000 [3], the GPEI Strategic
Plan 2013-2018 [4] calls for phased, but coordinated ces-
sation of the three OPV serotypes, starting with coordi-
nated cessation of serotype 2-containing OPV (OPV2
cessation) in April 2016 [5]. The risks associated with
OPV use include the relatively predictable cases of
vaccine-associated paralytic poliomyelitis (VAPP) in a
small fraction of OPV recipients and close contacts, the
emergence of circulating vaccine-derived polioviruses
(cVDPVs) in populations with low immunity to poliovirus
transmission that can behave like WPVs and cause out-
breaks, and possible reintroduction of immunodeficiency-
associated vaccine-derived polioviruses (iVDPVs) from
rare individuals with B-cell-related primary immunodefi-
ciencie diseases (PIDs) who can continue to excrete polio-
viruses for years [2]. In addition, after cessation of one or
more OPV serotypes, any OPV of the withdrawn sero-
type(s) that mistakenly remains in the field or insuffi-
ciently contained in laboratories and vaccine production
sites poses a risk of reintroducing a live poliovirus (LPV)
in increasingly susceptible populations [6]. For any given
serotype, new recipient VAPP cases of that serotype in im-
munocompetent individuals will almost immediately stop
after OPV cessation, but cVDPVs can still evolve from
continued circulation of OPV-related strains and get rec-
ognized through paralytic cases within about a year or so
of OPV cessation in populations with insufficient immun-
ity at the time of OPV cessation [7]. If the world can suc-
cessfully control these cVDPV outbreaks, then long-term
iVDPV excretors represent the primary OPV-associated
risk of outbreaks.
While any cVDPVs would likely emerge at a time of
relatively high population immunity to transmission given
the recent use of OPV in most countries [7], after OPV
cessation, countries will only use the inactivated poliovirus
vaccine (IPV) for polio immunization. While IPV appears
to provide sufficient population immunity to prevent
transmission in populations with high hygiene levels and
low fecal-oral transmission [8–10], recent asymptomatic
circulation of serotype 1 WPV (WPV1) in parts of Israel
despite very high IPV routine immunization coverage
strongly suggests that IPV-induced immunity alone can-
not prevent or stop transmission in some settings [11, 12].
Modeling further suggests that population immunity to
poliovirus transmission will drop significantly and fairly
quickly after OPV cessation in most developing countries,
regardless of IPV use due to both new birth cohorts that
only receive IPV and waning immunity in those previously
immunized or exposed to LPVs [13]. Strategies to respond
to and control any iVDPV-associated outbreaks in devel-
oping countries long after OPV cessation require careful
consideration, because using OPV could re-introduce
large amounts of LPV at a time of low population immun-
ity, and IPV may not provide sufficient population im-
munity to stop its transmission. Recognizing this risk, in
2006 an Institute of Medicine committee recommended
the development of one or more polio antiviral drugs
(PAVDs) [14]. Currently, one compound (pocapavir) exists
with proven ability to stop poliovirus excretion in a frac-
tion of immunocompetent individuals based on one small
clinical trial, and other compounds remain in develop-
ment [15].
We previously estimated the prevalence of long-term
iVDPV excretors (i.e., defined as either prolonged excre-
tors with between 6 months and 5 years of excretion, or
chronic excretors with over 5 years of excretion) and as-
sociated probabilities of post-OPV-cessation outbreaks
based on the information available as of late 2005 [2].
The analysis relied on limited studies that observed no
long-term iVDPV excretors among 384 persons with
PIDs studied [16, 17] and knowledge about 4 identified
asymptomatic and active long-term excretors [2]. We
accounted for uncertainty by characterizing a wide distri-
bution of the risk that included an upper bound for the
prevalence of long-term excretors of 140 in upper middle-
and high-income countries before OPV cessation [2]. The
probability distribution for the ratio of reported to actual
long-term excretors reflected the findings from screening
studies [16, 17] and an estimate of approximately 1:100,000
people affected with agammaglobulinemia, which repre-
sents only one of the many PIDs that can lead to long-
term excretion. The 2006 analysis [2] emphasized the need
for additional studies that would reduce uncertainty.
Since 2006, the GPEI intensified the search for asymp-
tomatic long-term iVDPV excretors through screening
studies and for paralytic long-term iVDPV excretors
through the acute flaccid paralysis surveillance system.
Consistent with this intensification, the average annual
number of identified long-term excretors increased by a
factor of 2.5 from 2000–2005 to 2006–2013 [18]. Im-
provements in the quality of health care delivery in mid-
dle - income countries may also imply increased survival
of PID patients and affect the prevalence of long-term
excretors. The increased number of individuals with
PIDs screened for long-term iVDPV excretion led to
some identified long-term excretors, and the updated
data provide better information to characterize the
bounds of the proportion of PID patients with long-term
iVDPV excretion [19–21].
The accumulation of new evidence about PID preva-
lence, survival, and long-term excretion of polioviruses
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and the parallel development of PAVDs motivate a re-
analysis of the iVDPV risks going forward and consider-
ation of the potential impact of PAVDs. In addition, the
serotype-specific OPV vaccination and cessation strat-
egies that did not exist at the time of our prior analysis
motivate the consideration of serotype-specific differ-
ences in iVDPV risks [22]. We developed a stochastic,
discrete-event simulation (DES) model to estimate the
prevalence of long-term iVDPV excretors up until and
after OPV cessation based on current evidence. The
model incorporates the available new evidence about
iVDPVs and explores the potential impact of PAVDs on
iVDPV prevalence for use in integrated global modeling
of long-term poliovirus risk management policies [23].
Background
Immunocompetent individuals infected with poliovirus
typically excrete for several weeks (mean around 30 days)
and no longer than 3 months [8, 9, 24, 25]. However, a
small fraction of individuals with B-cell-related PIDs can
excrete for longer [26–30]. The GPEI maintains a regis-
try of known long-term excretors that included 73 im-
munodeficient patients with evidence of more than
6 months of poliovirus excretion identified prior to 2014
[18], which largely overlaps with the 68 long-term polio-
virus excretors listed in a recent review [31]. Of the 73
known long-term excretors, 13 (17 %) presented with
common variable immunodeficiency disease (CVID),
while the remainder presented with other PIDs (oPIDs),
including not further specified PIDs (16), severe com-
bined immunodeficiency disease (SCID)(14), hypogam-
maglobulinemia (11), X-linked agammaglobulinemia (8),
agammaglobulinemia (6), major histocompatibility com-
plex class II molecule deficiency (2), humoral and cellular
immunodeficiency (1), HLA-DR-associated immunodefi-
ciency (1), and immunodeficiency-centromeric instability-
facial abnormalities (1). Six of the 13 (36 %) long-term
excretors with CVID fit the criteria for chronic excretion
[29, 30, 32–34] and one additional CVID patient died ap-
proximately 5 years after the probable onset of infection
[35], while none of the long-term excretors with oPIDs ex-
creted longer than 5 years.
The overall prevalence of PIDs globally remains highly
uncertain due to the large number of PID conditions,
differences in case definitions, and variability between
countries in both genetic profiles (e.g., consanguinity)
and survival rates of PID patients [16, 36, 37]. Estimates
of the prevalence of CVIDs reported to PID registries
generally range from 1:10,000 to 1:100,000 people with a
best estimate around 1:50,000 people for high-income
countries [18]. One US telephone survey of self-reported
PIDs without clinical verification reported 8 CVID and
15 oPID patients from approximately 10,000 surveyed
households representing approximately 27,000 people.
These numbers translate into prevalence rates of CVIDs
and oPIDs of approximately 1:3,300 and 1:1,800 people,
respectively [38]. However, the study concludes that “the
true incidence and prevalence of these conditions will
never be known until there is newborn or population
screening for these defects [38], p. 501.” Notably, other
authors extrapolated these results globally without any
adjustments for study bias or differential survival of PID
patients in different countries and estimated an unrealis-
tic global prevalence as up to 6 million PID patients
worldwide [39]. This estimate contrasts sharply with the
approximately 77,000 PID patients reported in a survey
among physicians in 225 Jeffrey Modell Foundation Cen-
ters in 78 countries, which included approximately 8600
CVID patients [40]. With respect to oPIDs, one Minne-
sota county with a comprehensive medical record system
estimated an overall PID incidence for 2001–6 of 10.3
per 100,000 person-years, with an age-specific incidence
of approximately 22 per 100,000 person-years aged 0–5
years [41]. These rates do not directly translate into rates
per newborn due to imperfect diagnosis and time delays
associated with development of symptoms and diagnosis. A
study of VAPP in the US assumed an incidence of approxi-
mately 1 PID patient per 10,000 births in the US [42].
Intravenous immunoglobulin (IVIG) therapy reduces
morbidity and probably also mortality. Patients with
CVIDs can survive for many years with appropriate and
uninterrupted IVIG therapy, although they experience
higher death rates than the general population even in
developed countries [36, 37, 41, 43, 44]. The life expect-
ancy of other types of PIDs varies [36], with more severe
forms (e.g., SCID) rarely surviving beyond 1 year of age
in developing countries [20], and less severe forms with
life expectancy more similar to CVID patients (e.g.,
patients with other hypogammaglobulinemia). The on-
set of symptoms varies widely among CVID patients,
with an average of approximately 25 years [43–45],
while severe oPIDs most commonly associated
with long-term poliovirus excretion typically occur
earlier in life. Over the past 25 years, IVIG therapy
has become the standard of care for PID patients in
developed countries [46], and some developing coun-
tries recently began providing IVIG to identified PID
patients through their health care systems [20]. The
global supply of IVIG remains limited [46] and effect-
ive treatment requires consistent and high quality
IVIG administration, with any disruptions exposing
patients to a risk of developing infectious disease
complications [34].
Although the acute flaccid paralysis surveillance sys-
tem cannot detect individual asymptomatic long-term
excretors, the GPEI registry identified 16 asymptomatic
long-term excretors through other sources (primarily
known PID patients in higher-income countries identified
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by the treating physician). In addition, environmental sur-
veillance activities in several countries identified 9 highly
divergent VDPVs likely from different immunodeficient
chronic excretors in sewage, but they could not link the
detected viruses to any individuals with PIDs [18, 47–50].
The detection of these viruses suggests the existence of
significantly more asymptomatic long-term iVDPV excre-
tors than the 16 individuals known to the GPEI.
Table 1 summarizes the results of several screening
studies that provided additional evidence about the fre-
quency of long-term poliovirus excretion. All studies
combined that screened PID patients for long-term
excretion detected only 1 prolonged excretor (a CVID
patient in Sri Lanka) out of 318 CVID patients (0.3 %)
and 978 total PID patients (0.1 %) (Table 1). Another
child in Sri Lanka with SCID died while infected and
appeared as a long-term excretor in some publications
assuming infection following the first OPV dose received
[18, 35, 51] but not in other publications based on
the duration of documented excretion [20, 52], which
reflects uncertainty about the date of the OPV expos-
ure that initiated the infection. Given the low num-
bers of observations overall, inclusion of this excretor
would double the apparent rate of long-term polio-
virus excretors per PID patient (e.g., from 1 in 978 to
2 in 978). A 7-country screening study identified 17
total poliovirus excretors and followed these individ-
uals longitudinally until they stopped excreting or
died. In this study, 6 excretors died within 6 months
while still excreting poliovirus. Of the remaining 11
excretors, 10 stopped excreting spontaneously within
6 months, while 1 spontaneously stopped excreting
after 8 months [52].
PID patients with poliovirus infections remain vulner-
able to VAPP, and the GPEI identified most long-term
excretors when they presented with VAPP (i.e., 57 of 73,
78 %) [18]. A retrospective analysis of all 37 immunode-
ficient VAPP cases reported in the United States be-
tween 1975 and 1997 found 6 months of excretion or
more for 6 of 31 (19 %) patients with follow-up samples
available, including 1 chronic excretor with CVID [53].
Some patients developed fatal VAPP after a long period
of excretion, while others survived and continued to ex-
crete iVDPVs long after VAPP onset, and both asymp-
tomatic long-term excretors and those with VAPP may
spontaneously clear the infection [2, 18, 53]. For most
known long-term excretors, we could not determine
their IVIG therapy status at the time of OPV infection,
but the majority of those with available data appeared to
have acquired the OPV infection before the start of IVIG
therapy. However, at least 2 excretors started IVIG ther-
apy before the estimated onset of the long-term OPV in-
fection [20, 34]. Thus, IVIG therapy may reduce the
probability of acquiring an OPV infection or of an OPV
infection establishing persistent replication, but it does
not completely prevent long-term infection.
Methods
Stages of PID disease and OPV infection
Figure 1 provides our conceptual diagram of the pro-
gression of PID patients through various clinical and
poliovirus excretion stages (large boxes) with inflows
Table 1 Results of screening studies for long-term iVDPV excretion among individuals with PIDs




Poliovirus excretors iVDPV excretors Patients with > 6 months
of documented excretion
Source(s)
Bangladesh 13 0 1 0 0 [52]
Brazil 95 70 3 0 0 [16]
China 167 22 3 0 0 [52]
Egypta 15 3 2 0 0 [21]
Iran 43 16 1 0 0 [52]
Italy 38 0 0 0 0 [17]
Mexico 33 5 1 0 0 [16]
Philippines 70 6 1 0 0 [52, 60]
Russia 136 27 0 0 0 [52]
Sri Lanka 51 13 5 2 1b [20, 52]
Tunisia 16 2 4 0 0 [61]
Tunisia 82 14 6 0 [19, 52]
United Kingdom 125 65 0 0 0 [16]
United States 94 75 0 0 0 [16]
Total 978 318 27 2 1
aPreliminary results
bThe prolonged iVDPV excretor was diagnosed a CVID patient
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and outflows from the stages indicated by arrows with
solid lines. The arrows with dotted lines indicate
model inputs that influence the flows. The accumula-
tion of individuals in the stages provides the overall
prevalence in the population, with the total number
in the two stages on the right representing the preva-
lence of long-term (i.e., prolonged and chronic) excre-
tors. We include trees with branches within some of
the stages to indicate stratification of stages into dif-
ferent groups that may experience different outflows
going forward. For example, the death rate for clinical
PIDs depends on the type of PID and effective treat-
ment with IVIG. Death rates, treatment probabilities,
and OPV infection rates further change over time and
vary between countries. Infected patients may develop
VAPP at any time as they move through the OPV,
prolonged, and chronic infection stages, so long as
the infection continues and the individuals survive.
Figure 1 suggests that once individuals recover from
infection, they can potentially become re-infected. No
known cases of longterm re-infection after recovery
from a long-term infection exist, but some evidence
exists of many repeated poliovirus and other entero-
virus infections in a PID patient, with one poliovirus
infection of at least 4 months [54].
Discrete-event simulation model
The population of long-term excretors changes over
time, and consequently modeling the risks should in-
volve appropriate characterization of the dynamics of ac-
cumulation of excretors and their progression through
different stages of infection until they ultimately either
stop excreting spontaneously or die. Based on our un-
derstanding of how PID patients move through various
clinical and OPV infection stages (Fig. 1), we developed
a DES model to estimate long-term poliovirus excretor
prevalence over time following each PID patient for life.
The model uses a discrete time step of 1 month. We use
the stratification from an integrated global model (i.e.,
the global model) that assigns all countries to epidemio-
logical blocks of approximately 100 million people in
2013 classified by polio vaccine use as of 2013 (i.e.,
OPV-only, sequential IPV/OPV, or IPV-only), geo-
graphic proximity, and economic status [23, 55]. We es-
timated poliovirus basic reproduction number (R0)
values for each block based on prior modeling experi-
ence and use R0 as a proxy for many factors that affect
poliovirus transmission and the health system quality by
correlating R0 with vaccine coverage and take rate, ex-
tent of fecal-oral transmission, and costs. Table 2 pro-
vides the resulting global R0 distribution for the different
Fig. 1 Conceptual diagram of states for individuals in the population with respect to the development of various stages and types of long-term
iVDPV excretion. Arrows between boxes indicate flows that represent PID disease and poliovirus infection progression, while trees within boxes
represent branching between distinct pathways that imply one or more different downstream rates and probabilities. Notation (see also list of
abbreviations): b, birth rate; d1, duration of infection for clinical PID patients with typical OPV infection; d2, duration of infection for prolonged
excretors; d3, duration of infection for chronic excretors; Dgen, death rate for general population (by age); Dpid, death rate for clinical PID patients
(by, PID category and receipt of effective treatment); eAVrate, effective rate of PAVD use; N, population size; OPVrate, combined primary (i.e.,
vaccination) and secondary OPV infection rate (by age, OPV use over time, diagnose status, and IVIG rate); Tchr, time to move from prolonged to
chronic infection; Tonset, average time to onset of clinical PID; Tpro, time to move from OPV to prolonged infection; VAPPfrate(1, 2, and 3), VAPP
fatality rate for PID patients (during OPV infection, prolonged excretion, and chronic excretion, respectively)
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Table 2 Assumed distribution of wild poliovirus serotype 1 R0 values for the different income level and current polio vaccine use strata, as used in the global model, and













Number of blocks assigned to each R0 (for WPV1)
4 5 6 7 8 9 10 11 12 13
Low OPV-only 0.86 33 N/A 8 0 0 0 0 0 1 3 2 1 1
Lower middle OPV-only 2.48 33 N/A 25 0 0 1 4 5 2 0 10 1 2
Upper middle OPV-only 1.87 20 N/A 19 0 0 1 16 2 0 0 0 0 0
Upper middle IPV/OPV 0.50 20 58 7 0 2 3 2 0 0 0 0 0
High IPV/OPV 0.23 10 50 2 0 0 0 2 0 0 0 0 0 0
High IPV-only 1.02 10 50 10c 2 7.7 0.3 0 0 0 0 0 0 0
aDoes not include countries with unspecified income level totaling approximately 23 million people and two high-income countries that still use OPV-only totaling approximately 34 million people (all as of 2013);
Assigns 67 million people in IPV/OPV-using lower middle-income countries to IPV/OPV-using upper middle-income blocks, 74 million people in IPV-only using upper middle-income countries to IPV-only-using
high-income blocks, and 23 million people in OPV-only-using high-income countries to OPV-using lower or upper middle-income blocks
bYears relative to beginning of burn-in period 65 years ago (i.e., 1950)















strata of income levels and polio vaccine use as of 2013.
Because the accumulation of PID patients increases rela-
tively slowly in the model, we use a long burn-in period,
assuming the same general population death rates
throughout, but increasing treatment fractions (see
below). Table 2 includes the assumptions about when
IPV-only or IPV/OPV starts during the burn-in period
for different income levels.
Births and characteristics determined at birth
Table 3 presents the events in the DES model, with esti-
mates of the probabilities based on the limited available
evidence and judgment. For each block, we generate the
monthly number of births (b) over time based on demo-
graphic data [56]. Using the estimated fraction of births
with PIDs (Ppid), the model generates the total number
of newborns in each month with a genetic predisposition
of each PID category (CVID or oPIDs) using a random
draw from a Poisson distribution with rate b × Ppid. The
model differentiates CVID from oPIDs because it as-
sumes that only CVID patients may develop chronic
poliovirus excretion. This level of stratification combines
all oPIDs into one category, despite the wide spectrum
of conditions, disease severity, treatments, survival, and
possibly also different abilities to become infected and/
or clear poliovirus, because insufficient data exist to sep-
arately model all PID defects. At birth, we also randomly
determine whether each PID patient will become a long-
term excretor if infected with OPV after onset of clinical
symptoms resulting from the PID (upper section of
Table 3). The probability of potential long-term excre-
tion (i.e., if infected with OPV after PID onset and sur-
viving long enough) represents a key uncertain input.
Although we do not know whether individual host prop-
erties or random events associated with the OPV infec-
tion (e.g., the replication site) determine the ability to
excrete long-term, we assume a pre-determined patient-
specific ability to excrete long-term, if surviving long
enough and infected after clinical PID onset. In the ab-
sence of resource constraints and practical consider-
ations, the ideal screening study would follow a large
number of PID patients over many years after PID onset
to determine when they become infected with OPV and
when they recover. The existing screening studies in
Table 1 only provide a cross-section of PID patients and
identified individuals excreting at a given point in time,
with limited follow-up of only those found excreting.
Depending on the interpretation of the data discussed
above, estimates of the rate of long-term excretion per
PID patient may range from approximately 0.1 % (i.e.,
the proportion of all PIDs found to excrete poliovirus
during follow-up of cross-sectionally screened PID pa-
tients) [52] to approximately 10 % (i.e., the proportion of
surviving patients with poliovirus excretion at time of
cross-sectional screening found to excrete long-term)
[52] or as high as almost 20 % (i.e., the proportion of
surviving immunodeficient VAPP patients found to
excrete long-term) [53]. The first estimate provides a
lower bound of potential long-term excretors because it
excludes excretors who did not yet become infected at
the time of screening or who already stopped excreting.
The 10 % estimate may represent an overestimate of the
true proportion because its denominator skews towards
long-term excretors (since they remain more likely to
excrete poliovirus at the time of screening). The 20 %
estimate provides an overestimate if VAPP is more com-
mon for long-term than typical excretors with a PID,
which appears plausible given that long-term excretors
cannot rapidly clear polioviruses and a longer infection
implies a greater chance of the virus entering the central
nervous system. We assume that 1 % of PID patients
may become a prolonged excretor if infected and surviv-
ing (Table 3). Although close to half of the identified
CVID patients with long-term excretion exhibit chronic
excretion, we assume that relatively more prolonged
than chronic excretors with CVID go undetected due to
their shorter period of excretion, implying a smaller
probability (0.5 %) of a CVID patient becoming a
chronic excretor if infected and surviving.
PID survival and treatment
The remainder of Table 3 lists events and associated
probabilities that may occur at monthly intervals over
the lifetime of the PID patient, including death prior
to clinical PID onset based on age-specific general
population death rates in each income level [56].
After clinical PID onset, we assume different monthly
probabilities of death depending on the PID category
(i.e., CVID or oPID), treatment status, and R0 for
WPV1 in the population in which the PID lives.
Figure 2a shows the assumed baseline survival curves
for effectively treated and not effectively treated PID
patients, and Fig. 2b shows the assumed treatment
fraction as a function of time in each income level.
We constructed the baseline survival curve for treated
CVID patient from a longitudinal study of CVID patients
in Europe [44], which we assume applies for CVID
patients living in populations with an R0 of 4 or 5. From
the survival curve, we compute the monthly probability of
death D(t1) between t1 and t2 months after CVID onset
as D(t1) = 1-S(t2)/S(t1)1/(t2-t1), where S(t1) and S(t2) repre-
sent the proportion surviving t1 and t2 months after
CVID onset, respectively. For oPIDs, we constructed a
baseline survival curve based on judgment and limited
evidence that suggests very short survival for some oPIDs
(e.g., SCID), but a relatively long tail due to some oPID de-
fects with longer survival [36]. Based on data [44] that
suggest much shorter survival prior to widespread IVIG
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Table 3 Inputs for the DES model of long-term poliovirus excretor prevalence
Model input Base case value Source Notes
Births, by income level and polio vaccine
use as of 2013 [1/month]
Varies with time [23, 56] Using number of 0-year old children as of 2013,
divided by 12 months; stratification by income
level and polio vaccine as of 2013 as in Table 2
Probabilities of attributes determined at birth
PID pre-disposition [41] Based on reported annual total PID incidence
in 0–5 year olds during 2000–2006, attributing
21 % to CVIDs based on total reported fraction
of new PID cases, excluding IgA deficiency and
transient hypogammaglobulinemia in infancy
- CVID 1/32,000
- oPIDs 1/8,500




Assumes lower chance of becoming potential
chronic than prolonged excretor for CVIDs based
on limited observations of both; for oPIDs, no
known cases of chronic excretion exist- Prolonged, CVID or oPIDs 0.01
- Chronic, CVID 0.005
- Chronic, oPID 0
Monthly event probabilities and related relative probabilities
Death, general population, by income level Varies with age [56] Based on 2013 estimates of annualized death rates;
does not include fatal VAPP which may occur
separately; applies prior to clinical PID onset
Death, PID patients Varies with time since
onset/treatment
[20, 37, 44]B* Baseline monthly death rates calculated from
survival curves (Fig. 2), then multiplied by relative
monthly risk of death for R0 and treatment status;
does not include fatal VAPP which may occur
separately, and effect of treatment lapses, which
subject otherwise treated PID patients to the
untreated PID death rates for the duration of the
lapse
Relative monthly death rate vs. baseline,
by treatment status
B Apply death rates as a function of time since
treatment start for treated PID patients and since
PID onset for untreated patients
- Treated 1
- Untreated 5
Relative monthly death rate vs. baseline, by R0 B











- Lower middle-income 0.75
- Upper middle-income 0.1
- High-income 0.001
PID onset [44, 45] Corresponds to average of onset of approximately
25 (CVID) and 2 (oPIDs) years
- CVID 1/300
- oPIDs 1/24
Diagnosis [43–45] Corresponds to average diagnostic delay of
approximately 5 (CVID) and 1 (oPID) years
- CVID 1/60
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Table 3 Inputs for the DES model of long-term poliovirus excretor prevalence (Continued)
- oPIDs 1/12
Primary OPV infection, if OPV-only RI and not
diagnosed with PID
B Defined as monthly probability of infection with any
serotype due to receipt of OPV; assumes 3 OPV
infections during primary vaccination in first year
of life, 1 infection from OPV booster dose during
ages 1–4 in high-income countries, 1 annual
infection from OPV supplemental immunization
activity (SIA) doses during ages 1–4 in other countries,
and no OPV doses after age 4
- Any income level, age 0 1/4
- Not high-income, age 1-4 1/12
- High-income,age 1-4 1/48
- Any income level, age > 4 0
Primary OPV infection, if IPV/OPV RI and not
diagnosed with PID
B Assumes 2 instead of 3 OPV infections during
first year of life, with 1 additional infection during
ages 1-4
- Any income level, age 0 1/6
- Any income level, age 1-4 1/48
- Any income level, age > 4 0
Relative probability of primary OPV infection,
diagnosed vs. not diagnosed
0.1 B Assume contra-indications typically followed
for vaccination
Relative probability of secondary OPV
infection, diagnosed vs. not diagnosed
0.5 B Assume siblings will sometimes avoid live vaccines
Relative probability of long-term OPV
infection if treated vs. not treated
0.5 B Assumes some effect of IVIG on the ability of
an OPV infection to become persistent; excludes
treated PID patients experiencing a treatment lapse
Secondary OPV infection, if OPV-only RI [62, 63] B Defined as probability of infection with any
serotype due to secondary OPV exposure;
Baseline rates based on approximately 45 %
secondarily infected from OPV RI by age 20
months in US [62] and approximately 50 %
secondarily infected from SIAs in Oman and Cuba
[63, 64], assuming 1 SIA per year on average
- Not high-income, age 0-4 1/24
- High-income, age 0-4 0.029
- Not high-income, age 5-14 0.5 × 1/24
- High-income, age 0-4 0.5 × 0.029
- Not high-income, age > 14 0.25 × 1/24
- High-income, age >14 0.25 × 0.029
Relative probability of secondary OPV
infection in any income level if IPV/OPV RI vs.
high-income country with OPV-only RI
0.5 B
Probability of serotype-specific OPV infection
given any OPV infection before OPV2
cessation
[18] Based on distribution of isolated serotypes from
known long-term poliovirus excretors; see text
- Serotype 1 0.22
- Serotype 2 0.62
- Serotype 3 0.16
Probability of serotype-specific OPV infection
given any OPV infection, after OPV2 cessation
B Assumes same relative distribution of serotypes
1 and 3 after OPV2 cessation as before OPV2
cessation; see text
- Serotype 1 0.58
- Serotype 2 0
- Serotype 3 0.42
Recovery from OPV infection, by time since
onset of infection
[2, 18, 65] B Implies average duration of approximately 3
months for a “typical” infection (truncated at 6
months), which is somewhat longer than
immunocompetent individuals, consistent with
observations from Finland;[65] 2 years for a
prolonged infection (truncated at 5 years), and
10 years for a chronic infection (not truncated)
- Typical, months 0-4 1/3
- Typical, month 5 1
- Prolonged, month 0-5 0
- Prolonged, months 6-58 1/18
- Prolonged, month 59 1
- Chronic, month 0-59 0
- Chronic, from month 60 1/120
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Table 3 Inputs for the DES model of long-term poliovirus excretor prevalence (Continued)
VAPP [18, 42, 53] B Based on US VAPP incidence by PID category
and calibration to reported paralytic long-term
excretors (see text); assumes no chance of VAPP
if effectively treated (i.e., with IVIG), excluding
during treatment lapse
- CVID, not treated 0.004
- oPIDs, not treated 0.008
- Any PID, treated 0
Fatal VAPP [53, 66] Based on case-fatality rates among 6 immunodeficient VAPP
patients in Iran and 36 immunodeficient VAPP
cases in the US; for the latter, we assume that a
death within a year of VAPP onset represents
death associated with VAPP (even in the case of
another cause of death indicated) due to comorbidity
- Low-income countries 0.5
- Lower middle-income countries 0.4
- Upper middle-income countries 0.3
- High-income countries 0.14
Notes: * B indicates estimate based on judgment
Fig. 2 Assumed baseline survival curves for PID patients in populations with R0 values for WPV1 of 4 or 5 and assumed treatment fractions as a
function of time, by income level. a Baseline survival curves, compared with reported survival for CVID patients in high-income countries [34].
b Fraction of PID patients treated with IVIG, based on literature [20, 26, 30, 31, 36, 45] and judgment
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treatment in high-income countries, we assume 5-fold
higher monthly probabilities of death for CVID patients
and an equal relative monthly risk of death for untreated
compared to treated oPID patients (Table 3). We assume
that even for treated PID patients, relative death rates in-
crease with increasing R0, because higher poliovirus R0
values correlate with poorer hygiene and sanitation condi-
tions. Thus, for treated CVID patients, we assume
monthly death probabilities of up to 50 times (i.e., for the
highest R0 value of 13) the monthly death probabilities
calculated from the baseline survival curves (Table 3). We
further factor in the possibility of IVIG-treatment lapses
using the monthly income level-dependent lapse probabil-
ities in Table 3, assuming these represent independent
events and include both failure to receive IVIG during a
month or reduced quality of the polio or other antibodies.
If an IVIG-treatment lapse occurs, then we assume the
PID patient becomes subject to the untreated monthly
death probability for the time of the lapse. Given that ef-
fective treatment depends on delivery through a com-
pletely functional health system, we assume lower
treatment fractions in lower income levels, with some pro-
jected increase over time (Fig. 2b). During simulation, if
the proportion of PID patients receiving treatment (with
or without lapse) equals less than the assumed treatment
fraction for a given month, then we randomly add PID pa-
tients to the pool of treated patients until the proportion
treated is no longer smaller than the assumed treatment
fraction.
PID onset, diagnosis, OPV infections, and VAPP
Further events for all surviving PID patients include on-
set of PID symptoms and diagnosis and events related to
OPV infection, including the 1) monthly probability of
primary and secondary OPV infection that depends on
poliovirus vaccine use (i.e., OPV-only, IPV/OPV, or 0 if
no OPV use), age, income level, diagnosis status, treat-
ment status, and serotype, 2) monthly progression of
OPV infection that depends on the potential for long-
term poliovirus excretion determined at birth, and 3)
monthly probability of developing VAPP while infected,
with an income-level dependent probability of fatal
VAPP. When a primary OPV infection occurs during
simulation (i.e., a clinical PID patient receives OPV), we
independently sample the serotype(s) based on the sero-
type probabilities in Table 3, which implies some possi-
bility of 2 or 3 concurrent serotypes. For secondary OPV
infections, we assume only one serotype based on the
probabilities in Table 3. We assume probabilities of the
serotype(s) excreted based on limited evidence from the
iVDPVs isolated to date (Table 3) [18]. After OPV2 ces-
sation, removal of the serotype 2 component implies no
new creation of iVDPV2s (i.e., unless introduced for out-
break response or through an unintentional or intentional
event). We assume no change in the overall rate of OPV
infections after OPV2 cessation, with new infections in-
volving serotypes 1 and/or 3 according to the same rela-
tive likelihood of serotypes 1 and 3 as before OPV2
cessation (Table 3). Similar to the very low estimated
VAPP rate (i.e., approximately 1 per million) for first
poliovirus infections in immunologically competent indi-
viduals [42], VAPP also represents a rare event for PID pa-
tients, with 4 CVID and 33 oPID patients reported with
VAPP in the US during the 23-year period 1975–1997
[53]. Assuming approximately 400 annual PID births [42]
in the US and that 20 % of PID patients represent CVIDs
(Table 3), this translates into VAPP rates of 2200 and 4500
per million first infections in CVID and oPID patients, re-
spectively. To translate these into monthly probabilities of
VAPP given OPV infection, we assume that the GPEI
identified all paralytic long-term poliovirus excretors that
occurred during the last 5 years (i.e., 26 paralytic long-
term excretors during 2009–2013) [18]. We then
multiply the estimated rates above to obtain the same
cumulative number of paralytic poliovirus excretors
during 2009–2013 in the model as reported, which
makes the rates depend on all other model assump-
tions. This approach results in monthly VAPP prob-
abilities of 0.004 and 0.008 for CVID and oPID
patients, respectively. Thus, while VAPP clearly repre-
sents a very high risk for long-term excretors, VAPP
onset may not occur until many years of the OPV
infection if at all [34, 53] and one known chronic
excretor continues to excrete after approximately
30 years without development of VAPP to date [57].
Effect of PAVDs
With respect to the use of PAVDs, we assume that at
least 40 % of long-terms excretors may clear the virus
within 5 days if they receive a PAVD regimen, based on
the results of a small clinical trial of pocapavir in im-
munocompetent subjects (Table 3) [15]. Assuming that
immunodeficient patients would respond as well as im-
munocompetent subjects, 40 % represents a lower
bound given that some subjects apparently resistant to
the drug potentially acquired resistant virus from other
subjects in the trial after clearing their initial infections
[15]. To provide bounds on the potential impact of
PAVDs, we considered an upper bound of 90 % drug ef-
fectiveness, reflecting either higher effectiveness of poca-
pavir or the potential effectiveness of combining
multiple compounds. We further considered three sce-
narios of PAVD use: 1) the status quo, which assumes
no availability of the PAVD and provides a baseline for
comparison, 2) passive PAVD use, which assumes that
50 % of iVDPV excretors identified by previously experi-
encing and surviving VAPP receive PAVDs for one
month in January, 2020, and 3) active PAVD use, which
Duintjer Tebbens et al. BMC Infectious Diseases  (2015) 15:379 Page 11 of 18
represents a hypothetical upper bound and assumes
90 % of all iVDPV excretors receive PAVDs for one
month in January, 2020. Both PAVD scenarios further
administer PAVDs according to the same fractions to
any long-term excretors that develop paralysis after
January, 2020. If an excretor receives PAVDs, we ran-
domly determine whether the infection clears based
on the effectiveness assumption (i.e., 40 % or 90 %)
and assume this occurs within a month of the start
of PAVD treatment.
To perform analyses that demonstrate the global
iVDPV prevalence behavior from the DES model with or
without PAVDs, we run 1000 stochastic iteration of the
DES model for the different types of populations in the
global model with appropriate monthly death probabil-
ities and treatment fraction [23], and then aggregate the
results.
Results
Figure 3 shows the baseline prevalence (i.e., without
PAVDs) of long-term iVDPV excretors by (a) income
level, (b) serotype, (c) prolonged vs. chronic excretors,
and (d) clinical manifestation. The estimated total global
prevalence in 2013 equals approximately 30 long-term
excretors, including approximately 27 active prolonged
and 4 active chronic excretors. The number of pro-
longed excretors includes potential chronic excretors
who did not yet progress past 5 years of excretion. In
the context of high levels of continued OPV use to
achieve eradication, the contributions of the relatively
small number of long-term excretors to overall transmis-
sion of LPVs remains small and not easily observable.
Thus, iVDPVs currently represent a relatively low and
unnoticeable risk, except in countries that already
switched to IPV-only routine immunization schedules
for which any long-term excretors may represent a
source of exposure to LPV. This includes high-income
countries that maintain very high routine immunization
coverage and benefit from relatively low R0 values such
that any transmissions that may occur will die out.
As suggested in Fig. 3a, countries in the upper middle-
income group, which includes about 2.5 billion people in
2013 (nearly 50 % of them in China), account for an esti-
mated 16 total long-term excretors (52 % of the global
estimate). Thus, while the high-income countries include
more long-term excretors per capita during OPV use,
they represent only approximately 1.2 billion people and
the majority of these countries stopped all OPV use
years ago, which already led to a decline in their long-
term excretor prevalence.
As suggested in Fig. 3b, after OPV2 cessation, the
prevalence of long-term serotype 2 excretors drops
sharply, but serotype 1 and serotype 3 excretors increase
because the first OPV infection now always occurs with
one of these two serotypes. Before cessation of all OPV
serotypes in 2019, prolonged excretors (including poten-
tial chronic excretors who excreted between 0.5-5 years)
attain approximately seven times the prevalence of
chronic excretors (Fig. 3c). However, after OPV cessation
of all serotypes, not surprisingly the prevalence of pro-
longed excretors drops quickly, while a few chronic
excretors continue to exist for over a decade. Most of
the chronic iVDPV excretors after OPV cessation of all
serotypes reside in upper middle- and high-income
countries, with the prevalence in low- and lower
middle-income countries dropping below the level of
high-income countries within a few years of OPV ces-
sation of all serotypes. Despite the relatively high
monthly VAPP rates continuing throughout each
long-term infection (Table 3), long-term excretors with
VAPP still account for only approximately 10 % of all
long-term excretors (Fig. 3d) because the remainder either
will recover or die before VAPP or will not experience
VAPP until later during their infection.
The results in Fig. 3 correspond to an average cumula-
tive incidence of approximately 200 long-term iVDPV
excretors during 2009–2013, compared to 33 reported
by the GPEI during this period [18]. Given our approach
for estimating VAPP rates, we obtain approximately the
same number of paralytic long-term excretors as reported
(i.e., 30 vs. 26), while the model estimates approximately
170 asymptomatic long-term excretors compared to 7 re-
ported asymptomatic long-term excretors. Overall, the
model suggests a global prevalence of approximately
30,000 PID patients in January, 2015 with suspected im-
munodeficiencies that may lead to longer times required
to clear poliovirus infections. Combined with the 30 esti-
mated current long-term excretors, this translates into a
rate of approximately 0.001 long-term excretors per PID
patient, consistent with the rate of approximately 0.001
observed among 978 PID patients screened for long-term
poliovirus excretion shown in Table 1.
Given the importance of chronic excretors for long-
term poliovirus risk management, we further compared
the model results with the limited evidence about
chronic excretors. The model estimates global CVID
prevalence in 2015 of approximately 14,000 patients,
compared to approximately 8,000 CVID patients known
to a large network of PID treatment centers in 78 coun-
tries [40, 58]. This suggests a large number of unidenti-
fied CVID patients globally. However, significant
uncertainty about the true global prevalence [38, 39]
complicates verification of this model result. The data
from chronic excretors identified since 1970 sum to ap-
proximately 53 person-years of chronic infection (i.e.,
not including the first 5 years of infection during the
prolonged excretion time) and suspected chronic excre-
tors detected through environmental surveillance of
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another 95 person-years (assuming a rate of 1.1 %
VP1 divergence per year), for a total of almost 150
person-years of detected chronic infection. The 1,000
stochastic iterations of the DES model yield an aver-
age of approximately 200 person-years of chronic infec-
tion. The difference reflects the expected large proportion
of asymptomatic chronic excretors (Fig. 3d) and the lack
of systematic identification of chronic excretors.
Figure 4 shows the impact on iVDPV prevalence from
the potential use of a PAVDs with low drug effectiveness
of 40 % in clearing the infection (Fig. 4a) or high drug
effectiveness of 90 % (Fig. 4b) for both PAVD use scenar-
ios. Consistent with the low proportion of symptomatic
iVDPV excretors in the model, relying on the occurrence
of VAPP in PID patients to identify long-term excretors
and treating 50 % of them leads to a negligible reduction
in the prevalence, particularly if coupled with low drug
effectiveness (Fig. 4a, red curve overlapping the black
curve). The hypothetical scenario of active PAVD use
with 90 % of all long-term excretors receiving PAVDs
suggests potentially larger benefits, especially for high
drug effectiveness (Fig. 4b, green curve). However, this
scenario would require significant efforts to scale-up
screening of PID patients in order to treat them. With the
lower bound of PAVD effectiveness of 40 %, the active
PAVD use scenario attains a 15 % reduction in iVDPV
prevalence 10 years after OPV2 cessation. In contrast,
with the upper bound of PAVD effectiveness of 90 %, the
same level of PAVD use results in a 79 % reduction in
iVDPV prevalence 10 years after OPV2 cessation.
Discussion
As we enter the polio endgame, modeling can provide
important insights about the different risks that may
occur, which may help to identify opportunities to man-
age them. This reanalysis of iVDPV risks suggests that
they may represent a larger concern after OPV cessation
than previously recognized, although significant uncer-
tainty remains. The estimated current prevalence of
long-term excretors remains higher than the base case
for our prior analysis based on the zero observed long-
term excretors in screening studies available at the time,
but lower than the prior upper bound estimate [2],
reflecting the current non-zero observation of long-term
Fig. 3 Prevalence of long-term iVDPV excretors in the absence of
PAVD use, based on the monthly averages of 1,000 iterations of the
DES model (a) Global and by income level (all serotypes, prolonged
and chronic excretors, and clinical manifestations combined). b By
serotype (all income levels, prolonged and chronic excretors, and
clinical manifestations combined). c By prolonged vs. chronic excretors
(all income levels, serotypes combined, and clinical manifestations
combined). d By clinical manifestation (all income level, serotypes,
and prolonged and chronic excretors combined)
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excretors in more recent screening studies (Table 1) and
our efforts to account for missing long-term excretors in
those studies [52]. The proportion of PID patients who
may develop prolonged or chronic excretion neverthe-
less remains a major uncertainty. Improved treatment of
immunocompromised individuals continues to increase
their survival, with treatment strategies increasingly
transferred to relatively lower-income countries, which
also contributed to the overall higher prevalence than
previously estimated for these countries [2]. The insuffi-
cient data and uncertainty imply limitations of our
model and results. For example, insufficient data exist to
model the properties of each PID defect in the combined
oPID category, but important differences certainly exist.
More serious forms of PID (e.g., SCID) may imply a
greater probability of long-term poliovirus excretion, but
also lead to reduced survival, particularly in developing
countries. However, treatment of SCID patients with
bone marrow transplantation may also make these pa-
tients effectively immunocompetent and remove them
from the risk pool altogether. In contrast, patients with
milder PID defects with longer survival (e.g., hypogam-
maglobulinemia) probably recover spontaneously from
poliovirus infections relatively early during prolonged
replication. Combining all oPIDs without a correlation
between survival and probability of long-term infection
given OPV exposure represents the conservative ap-
proach and may overestimate prolonged excretion.
Other significant uncertainties also impact the risk
estimates, which could lead to higher or lower estimates.
The relatively high assumed probabilities of potential
long-term excretion of 1 % (prolonged) or 0.5 %
(chronic) (Table 3) used to adjust for missing excretors
based on the limited cross-sectional screening studies
may contribute to overestimation of the model because
they exceed the observed rates of 0.1 % (prolonged) and
0 % (chronic). In contrast, our model may underestimate
the current prevalence of long-term excretors in high-
income countries by assuming that all high-income
countries that use IPV-only as of 2013 stopped IPV use
as early as the year 2000 (Table 2), while in reality some
countries (e.g., Japan) continued to use OPV-only until
recently. In addition, almost no data exits to quantify
PID survival in developing countries and therefore our
assumed survival rates could over- or underestimate the
risk. Although we present the average results of 1000 re-
alizations of the model, the stochastic events modeled
could lead to very different potential futures and even
with all of the new information collected since our prior
analysis [2], iVDPV risks remain highly uncertain and of
significant concern for polio endgame risk management.
Further studies should provide additional information
that may help to reduce uncertainties.
Table 4 highlights high-impact and reasonably feasible
research opportunities to reduce uncertainties in future
iVDPV risk estimates that we identified through the
model development process. The opportunities include
research to reduce uncertainty about key drivers of the
prevalence of iVDPVs after OPV cessation, such as retro-
spective analysis of global PID registries to better
characterize PID survival in low- and middle-income
countries, expanded (and if feasible) longitudinal polio-
virus screening of PID patients to better estimate the
probability of long-term excretion for PID patients, and
clinical trials with PAVDs involving long-term excretors
to determine the PAVD effectiveness in clearing polio-
virus infection. Other research opportunities may ad-
dress specific questions identified through the model
development process or provide better estimates of the
bounds of current true global long-term poliovirus
excretor prevalence. With the long lead time for
Fig. 4 Impact of PAVD use on iVDPV prevalence for different PAVD
use scenarios starting on January 1, 2020, based on the first 100
stochastic iterations of the DES model. a Lower bound on effectiveness
of a single PAVD compound (i.e., assuming 40 % of recipients recover
from infection). b Hypothetical upper bound on effectiveness of one or
more PAVD compounds (i.e., assuming 90 % of recipients recover
from infection)
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research, development, and implementation of risk man-
agement strategies and the long observation period re-
quired for longitudinal screening, the research
opportunities we identified represent urgent, although in
some cases potentially costly priorities. However, the po-
tential consequences of an iVDPV-associated outbreak
in a developing country after OPV cessation in the ab-
sence of a tested outbreak response strategy beyond the
first few years after OPV cessation will likely justify fur-
ther investments to improve iVDPV risk management.
Some lower-cost research opportunities, such as more
systematic reporting of timelines of events associated
with long-term excretors and continued follow-up [59]
beyond recovery from infection, may help resolve a
number of specific questions identified through our
modeling process. In addition to the questions in Table 4,
we identified many other specific theoretical questions
and practical issues not addressable by feasible, short-
term research. For example, a better understanding of
the immunological mechanisms of long-term poliovirus ex-
cretion and recovery would help inform model inputs and
address the question of reinfection. Assessing the impact of
iVDPV prevalence on risks after OPV cessation requires in-
tegration of the results from the iVDPV prevalence model
with a global poliovirus transmission model [23]. In this
context, the transmissibility of iVDPVs compared to
cVDPVs or WPVs represents an important uncertainty that
will significantly affect the risk of any transmission from
long-term excretors over time. While we cannot directly es-
timate R0 values for poliovirus, environmental sampling
and expanded stool surveys around known excretors may
provide data to inform assumptions going forward.
Table 4 High-impact research opportunities identified to address key questions and reduce uncertainty in future iVDPV risk estimates
Research opportunities Research questions
Retrospective analysis of global PID registries - What are the survival prospects of individuals in different PID
categories in different income levels (particularly CVIDs) and
how are they changing over time?
- How does IVIG treatment affect PID survival?
Expanded and longitudinal screening of PID patients
for poliovirus (with reporting of IVIG treatment status
for screened PID patients)
- What fraction of patients with different PIDs (CVID, SCID,
others) will develop prolonged and chronic excretion if
infected with OPV?
- How many prolonged and chronic excretors currently exist
globally?
- How does IVIG treatment affect the probability of developing
a long-term infection if infected with OPV?
Clinical trials with PAVDs involving long-term excretors - How effective are individual and combined PAVDs in clearing
poliovirus infections?
Systematic detailed reporting of timelines of events
for all known long-term excretors
- Does a PID patient who spontaneously recovered from a
long-term infection develop sufficient immunity to
prevent future long-term infections of the same or
other serotypes?
- How does IVIG treatment affect the probability of developing
a long-term infection if infected with OPV?
- What is the current survival and excretion status and the
estimated time of infection, recovery (if applicable) and death
(if applicable) for each known long-term excretor?
Continued follow-up of all identified long term excretors
(including after spontaneous recovery from infection )
- Does a PID patient who spontaneously recovers from a long-
term infection develop sufficient immunity to prevent
future long-term infections of the same or other serotypes?
- Do frequent concurrent enteric infections result in an increased
probability of spontaneous recovery from long-term
poliovirus infections?
Intensification of searches for PID patients causing
apparent iVDPVs isolated from the environment
- Who are the sources of apparent iVDPVs isolated from the
environment?
- What are the bounds on current chronic excretor prevalence
in countries that stopped using OPV?
Expanded environmental surveillance for apparent iVDPVs - What are the bounds on current chronic excretor prevalence?
- Can iVDPVs transmit widely?
Modeling of iVDPV introductions into the general
population after OPV cessation
- What are the expected consequences of prolonged and chronic
excretion beyond OPV cessation?
Expanded stool sampling around known long-term excretors - Are iVDPVs as transmissible as cVDPVs and WPVs?
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After OPV cessation, efforts to identify chronic excretors
will represent a necessity for risk management. If effective
PAVDs exist, then treating chronic excretors both to pro-
tect them from potentially developing VAPP and to protect
the rest of the population from exposure to LPVs will offer
an important strategy to reduce risk. Efforts to identify pa-
tients in the presence of an effective treatment strategy will
most likely benefit from the potential to prevent future
VAPP in these patients and may support widespread test-
ing of PIDs for poliovirus excretion, including asymptom-
atic patients. Development of a second compound (or
more) will potentially help to both motivate a scale-up of
screening for long-term poliovirus excretors and achieve
more impact of widespread PAVD use on the risk of
iVDPVs after OPV cessation. In contrast, in the absence of
any PAVDs, risk management efforts may focus on patient
education aimed at asking the patients to limit their expos-
ure to others (i.e., self-isolation to some degree). This will
represent a challenge given the asymptomatic nature of
most infections and the lack of incentives for patient
participation.
OPV cessation will ultimately stop the creation of new
long-term excretors, but it will take time for the chronic
excretors that exist at the time of OPV cessation to stop ex-
creting. Countries and the GPEI will need to recognize that
in a world without high levels of population immunity to
transmission derived from use of LPVs, iVDPVs will repre-
sent an important potential source for re-introduction of
poliovirus that requires active risk management.
Conclusions
Further research into PID incidence, survival, and long-
term excretion would reduce important uncertainties as-
sociated with the risk from long-term poliovirus excretors.
Efforts to develop a second polio antiviral compound to
increase PAVD effectiveness and/or to maximize the iden-
tification and treatment of affected individuals represent
important risk management opportunities for the polio
endgame.
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